- Home
- CMPX vs SLN Comparison
CMPX vs SLN Comparison
Compare CMPX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- SLN
- Stock Information
- Founded
- CMPX 2014
- SLN 1994
- Country
- CMPX United States
- SLN United Kingdom
- Employees
- CMPX N/A
- SLN N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- SLN Health Care
- Exchange
- CMPX Nasdaq
- SLN Nasdaq
- Market Cap
- CMPX 291.8M
- SLN 281.0M
- IPO Year
- CMPX N/A
- SLN N/A
- Fundamental
- Price
- CMPX $2.61
- SLN $5.92
- Analyst Decision
- CMPX Strong Buy
- SLN Buy
- Analyst Count
- CMPX 9
- SLN 5
- Target Price
- CMPX $12.67
- SLN $32.60
- AVG Volume (30 Days)
- CMPX 946.0K
- SLN 111.7K
- Earning Date
- CMPX 08-11-2025
- SLN 08-14-2025
- Dividend Yield
- CMPX N/A
- SLN N/A
- EPS Growth
- CMPX N/A
- SLN N/A
- EPS
- CMPX N/A
- SLN N/A
- Revenue
- CMPX $850,000.00
- SLN $27,701,000.00
- Revenue This Year
- CMPX N/A
- SLN N/A
- Revenue Next Year
- CMPX N/A
- SLN N/A
- P/E Ratio
- CMPX N/A
- SLN N/A
- Revenue Growth
- CMPX N/A
- SLN N/A
- 52 Week Low
- CMPX $0.77
- SLN $1.97
- 52 Week High
- CMPX $4.08
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- CMPX 60.92
- SLN 58.35
- Support Level
- CMPX $2.52
- SLN $5.33
- Resistance Level
- CMPX $2.71
- SLN $6.00
- Average True Range (ATR)
- CMPX 0.17
- SLN 0.44
- MACD
- CMPX 0.00
- SLN -0.03
- Stochastic Oscillator
- CMPX 68.64
- SLN 64.07
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.